NeoGenomics posts Q3 beat, raises full‑year guidance and announces CEO transition
NeoGenomics reported third‑quarter 2026 revenue of about $209 million, up roughly 11% year‑over‑year, with adjusted earnings of $0.07 per share beating estimates. The company lifted its full‑year revenue outlook to the high $800 million range and its adjusted EBITDA target to around $60 million. It also disclosed that CEO Tony Zook will step down and President Warren Stone will assume the CEO role on 4 January 2027.
Why it matters
The raised guidance signals higher expected sales and profitability, which analysts cite as a reason to maintain buy ratings (e.g., BTIG’s $28 price target). The leadership change is presented as occurring from a position of strength, suggesting continuity in strategy.
Key facts
- 1Q3 revenue was $209 million, up 11% YoY. finance.yahoo.com
- 2Adjusted earnings were $0.07 per share, beating estimates by $0.01. finance.yahoo.com
- 3Adjusted gross margins expanded by over 300 basis points. finance.yahoo.com
- 4Adjusted EBITDA for the quarter was $19 million. finance.yahoo.com
- 5Full‑year revenue guidance was raised to $807 million‑$809 million. finance.yahoo.com
- 6Adjusted EBITDA guidance for the year was raised to approximately $60 million. finance.yahoo.com
Open questions
- Full‑year revenue guidance is reported as $808 million in one source (2) and $807‑$809 million in another (6).
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.